domingo, 15 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· July 28, 2026

Stocks Mixed on Earnings Results and Weakness in Chipmakers

View original at nasdaq.com
Stocks Mixed on Earnings Results and Weakness in Chipmakers The S&P 500 Index ($SPX) (SPY) today is up +0.05%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.738%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.12%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Claimed to have struck facilities linked to Saudi Aramco in the Red Sea port towns of Jizan and Yanbu on Saturday

    60% confidence
  • Q2 earnings may increase by +23%, close to Q1's blowout earnings of +30%, which was more than double the +12% analysts had expected

    60% confidence
  • Forecasting Q3 net sales of $1.95 billion to $2.05 billion, weaker than the consensus of $2.11 billion

    60% confidence
  • Raised the possibility of intensified action against Iran

    60% confidence
  • Reported Q2 net sales of $10.40 billion, above the consensus of $10.03 billion

    60% confidence
  • Raising its full-year comparable EPS forecast to up +9% to +10% from a previous view of +8% to +9%

    60% confidence
  • Boosting full-year revenue forecast to $17.28 billion to $17.48 billion from a previous forecast of $17.15 billion to $17.35 billion, stronger than consensus of $17.28 billion

    60% confidence
  • Cutting full-year adjusted EBITDA estimate to $850 million to $925 million from a previous forecast of $940 million to $1.02 billion, below consensus of $970.3 million

    60% confidence
  • Downgraded RXO to sell from hold with a price target of $19

    60% confidence
  • Upgraded Intuitive Surgical to buy from hold with a price target of $500

    60% confidence
  • Forecasting Q3 core sales of $4.9 billion to $5.0 billion, the midpoint below the consensus of $5.0 billion

    60% confidence
  • Reported adjusted EPS of $3.70, better than the consensus of $3.51, and raised full-year adjusted EPS forecast to $11.80 to $12.20

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,580 documentos-fonte arquivados
Consulte estes dados → isubstrate.com